Benzoquinone

Benzoquinone

SCHEMBL1298413

O=C1C=CC(=O)C=C1.O=C1C=CC=CC1=O

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.61
RECQL P46063 2/20 0.61
TDP1 Q9NUW8 2/20 0.61
MAOA P21397 2/20 0.61
MAOB P27338 2/20 0.61
BCHE P06276 1/20 0.61
POLB P06746 1/20 0.61
ACHE P22303 1/20 0.61
APEX1 P27695 1/20 0.61
MAPK1 P28482 1/20 0.61
CASP1 P29466 1/20 0.61
BLM P54132 1/20 0.61
MDM2 Q00987 1/20 0.61
DHODH Q02127 1/20 0.61
HSD17B10 Q99714 1/20 0.61
APOBEC3G Q9HC16 1/20 0.61
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
ALOX12 P18054 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL113494 0.88
Water SCHEMBL27949772 0.84
Ammonia Solution, Strong SCHEMBL8627775 0.84 MAOA (0.36) ALDH1A1RECQLTDP1MAOAMAOB
Potassium SCHEMBL30715495 0.84
SCHEMBL30715500 0.84
SCHEMBL9149406 0.84
Formaldehyde SCHEMBL27513797 0.80 MAOA (0.33) ALDH1A1RECQLTDP1MAOAMAOB
Benzene SCHEMBL28145502 0.80 MAOA (0.37) ALDH1A1RECQLTDP1MAOAMAOB
Nitrogen SCHEMBL27904925 0.80 MAOA (0.33) ALDH1A1RECQLTDP1MAOAMAOB
SCHEMBL106540 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4981946-A Marine paint composition comprising quinone/polyamine polymer ERHAN SEMIH (US) 1991-01-01 US claimed
US-20210322337-A1 TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS PTC THERAPEUTICS, INC. 2021-10-21 US disclosed
US-20180303767-A1 TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS BIOELECTRON TECHNOLOGY CORPORATION (US) 2018-10-25 US disclosed
US-10039722-B2 Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells BIOELECTRON TECHNOLOGY CORPORATION (US) 2018-08-07 US disclosed
US-8795858-B2 Magnetic recording medium and method of manufacturing the same FUJIFILM CORPORATION (JP) 2014-08-05 US disclosed
US-8552572-B2 Resin composition for encapsulating semiconductor and semiconductor device using the same SUMITOMO BAKELITE CO., LTD. (JP) 2013-10-08 US disclosed
US-20110269776-A1 TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS EDISON PHARMACEUTICALS, INC. (US) 2011-11-03 US disclosed
US-20110229741-A1 MAGNETIC RECORDING MEDIUM AND METHOD OF MANUFACTURING THE SAME FUJIFILM CORPORATION (JP) 2011-09-22 US disclosed
EP-2362726-A1 TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS Edison Pharmaceuticals, Inc. (US) 2011-09-07 EP disclosed
US-20110124775-A1 RESIN COMPOSITION FOR ENCAPSULATING SEMICONDUCTOR AND SEMICONDUCTOR DEVICE USING THE SAME SUMITOMO BAKELITE CO., LTD (JP) 2011-05-26 US disclosed
WO-2010045220-A1 TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS EDISON PHARMACEUTICALS, INC. (US) 2010-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269776-A1 TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS GPX4, TXN2, TXNRD1 ALDH1A1 386/4885RECQL 997/4885TDP1 2191/4885
US-20180303767-A1 TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS GPX4, TXN2, TXNRD1 ALDH1A1 386/4885RECQL 997/4885TDP1 2191/4885
US-10039722-B2 Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells GPX4, TXN2, TXNRD1 ALDH1A1 386/4885RECQL 997/4885TDP1 2191/4885
US-20210322337-A1 TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS GPX4, TXN2, TXNRD1 ALDH1A1 386/4885RECQL 997/4885TDP1 2191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.